Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics is a commercial-stage biotech company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its first commercial product, Amtagvi (lifileucel), is approved in the U.S. and Canada for previously treated advanced melanoma and is given with lymphodepletion and Proleukin.
The company estimates Amtagvi could address over 30,000 advanced melanoma patients annually and is pursuing additional approvals in the UK, Australia, Switzerland and the EU. A Phase 3 trial (TILVANCE-301) is testing lifileucel plus pembrolizumab in frontline melanoma, while the IOV-LUN-202 registrational trial targets previously treated advanced non-squamous NSCLC.
Iovance has centralized manufacturing at its FDA‑approved Iovance Cell Therapy Center in Philadelphia, which has capacity for more than 5,000 patients per year and has produced TIL therapies for over 1,500 patients. As of February 13, 2026, there were 411,961,607 shares of common stock outstanding.
Iovance Biotherapeutics is a commercial-stage biotech company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its first commercial product, Amtagvi (lifileucel), is approved in the U.S. and Canada for previously treated advanced melanoma and is given with lymphodepletion and Proleukin.
The company estimates Amtagvi could address over 30,000 advanced melanoma patients annually and is pursuing additional approvals in the UK, Australia, Switzerland and the EU. A Phase 3 trial (TILVANCE-301) is testing lifileucel plus pembrolizumab in frontline melanoma, while the IOV-LUN-202 registrational trial targets previously treated advanced non-squamous NSCLC.
Iovance has centralized manufacturing at its FDA‑approved Iovance Cell Therapy Center in Philadelphia, which has capacity for more than 5,000 patients per year and has produced TIL therapies for over 1,500 patients. As of February 13, 2026, there were 411,961,607 shares of common stock outstanding.
Iovance Biotherapeutics reported strong topline growth for the fourth quarter and full year 2025 while remaining loss-making as it scales commercialization of Amtagvi. Fourth-quarter product revenue reached $86.8M, up from $73.7M a year earlier, contributing to full-year 2025 revenue of $263.5M versus $164.1M in 2024, meeting its $250M–$300M guidance range. Q4 gross margin improved to 50%, but total 2025 costs and expenses of $666.9M led to a net loss of $391.0M, or $(1.09) per share. Cash, cash equivalents and investments were $297.0M as of December 31, 2025, with an investor presentation indicating total cash of about $303M and runway into Q3 2027. Strategically, growth is driven by increasing Amtagvi demand in advanced melanoma, while the pipeline advanced with a U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer and multiple ongoing registrational and proof-of-concept trials in solid tumors.
Iovance Biotherapeutics reported strong topline growth for the fourth quarter and full year 2025 while remaining loss-making as it scales commercialization of Amtagvi. Fourth-quarter product revenue reached $86.8M, up from $73.7M a year earlier, contributing to full-year 2025 revenue of $263.5M versus $164.1M in 2024, meeting its $250M–$300M guidance range. Q4 gross margin improved to 50%, but total 2025 costs and expenses of $666.9M led to a net loss of $391.0M, or $(1.09) per share. Cash, cash equivalents and investments were $297.0M as of December 31, 2025, with an investor presentation indicating total cash of about $303M and runway into Q3 2027. Strategically, growth is driven by increasing Amtagvi demand in advanced melanoma, while the pipeline advanced with a U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer and multiple ongoing registrational and proof-of-concept trials in solid tumors.
IOVANCE BIOTHERAPEUTICS Chief Commercial Officer Daniel Gordon Kirby reported vesting of restricted stock units and related tax withholding. On February 10, 2026, 39,996 RSUs vested and were converted into the same number of common shares at $0 exercise price.
To cover mandatory taxes on this vesting, 16,450 common shares were withheld by the company at $2.60 per share, which the filing specifies is not an open market sale. After these transactions, Kirby directly holds 53,546 common shares and 80,004 RSUs from the February 10, 2025 grant, with remaining RSUs scheduled to vest in equal quarterly installments.
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of common stock of IOVANCE BIOTHERAPEUTICS INC as of 12/31/2025. State Street reports beneficial ownership of 20,161,445 shares, representing 5.1% of the company’s common stock.
State Street reports no sole voting or dispositive power, with 19,204,365 shares subject to shared voting power and 20,161,445 shares subject to shared dispositive power. Subsidiaries involved include SSGA Funds Management and various State Street Global Advisors entities. State Street certifies the holdings are in the ordinary course of business and not for changing or influencing control of Iovance.
Iovance Biotherapeutics, Inc. filed a report describing an updated corporate presentation it will use with healthcare conference audiences, analysts, current stockholders, and others. In that presentation, the company states it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of sales for its therapy Amtagvi. The updated slide deck is provided as Exhibit 99.1 to the report.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported a routine insider equity transaction involving its Chief Regulatory Officer. On 12/01/2025, restricted stock units (RSUs) covering 5,469 shares of common stock vested, and these shares were acquired at an exercise price of $0 as part of the equity award terms.
To cover mandatory tax withholding triggered by the RSU vesting, the company withheld 2,467 shares at a price of $2.23 per share, which was not an open market sale. After this withholding, the officer beneficially owned 215,859 shares of common stock directly. The filing also notes that 27,348 RSUs from the March 1, 2024 grant remain outstanding, scheduled to vest in equal quarterly installments, each RSU representing one share of common stock.
Iovance Biotherapeutics (IOVA) filed a Form S-8 to register an additional 1,000,000 shares of common stock for its 2020 Employee Stock Purchase Plan, which was amended on June 10, 2025. The shares are the same class as those previously registered for this plan.
The filing incorporates by reference earlier S-8 registrations related to the ESPP and includes customary exhibits, including the legal opinion and auditor consent.
Iovance Biotherapeutics filed its Q3 2025 10‑Q, reporting total revenue of $67.455 million and a net loss of $91.253 million. Year to date, revenue reached $176.731 million as Amtagvi and Proleukin sales scaled.
Operating costs remained heavy: cost of sales $38.477 million, R&D $75.174 million, SG&A $34.555 million, plus $5.143 million in restructuring charges, driving a loss from operations of $94.901 million. Cash used in operations for the first nine months was $249.843 million.
Liquidity was supported by $306.8 million in cash, cash equivalents, short‑term investments, and restricted cash as of September 30, 2025, and the company states it has sufficient capital to fund planned operations for at least the next twelve months. Shares outstanding were 396,967,970 as of October 15, 2025.
Iovance Biotherapeutics filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025 and recent updates. The press release is included as Exhibit 99.1.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL.
Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics (IOVA), reported transactions dated 09/02/2025 on a Form 4. The filing shows 52,086 shares of common stock acquired upon RSU vesting at no cash price and 22,127 shares withheld by the issuer to satisfy mandatory tax withholding at a reported withholding price of $2.19 per share. After these transactions the filing reports 456,690 shares beneficially owned following the vesting event and 434,563 shares remaining after the tax-withholding deduction. The filing also details newly vested restricted stock units (RSUs): 10,417 and 41,669, with resulting beneficial ownership figures shown in the form.